Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Perspectives and Limitations of Mesenchymal Stem Cell-Based Therapy for Corneal Injuries and Retinal Diseases

B. Hermankova, E. Javorkova, K. Palacka, V. Holan

. 2025 ; 34 (-) : 9636897241312798. [pub] -

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc25010379

The eye represents a highly specialized organ, with its main function being to convert light signals into electrical impulses. Any damage or disease of the eye induces a local inflammatory reaction that could be harmful for the specialized ocular cells. Therefore, the eye developed several immunoregulatory mechanisms which protect the ocular structures against deleterious immune reactions. This protection is ensured by the production of a variety of immunosuppressive molecules, which create the immune privilege of the eye. In addition, ocular cells are potent producers of numerous growth and trophic factors which support the survival and regeneration of diseased and damaged cells. If the immune privilege of the eye is interrupted and the regulatory mechanisms are not sufficiently effective, the eye disease can progress and result in worsening of vision or even blindness. In such cases, external immunotherapeutic interventions are needed. One perspective possibility of treatment is represented by mesenchymal stromal/stem cell (MSC) therapy. MSCs, which can be administered intraocularly or locally into diseased site, are potent producers of various immunoregulatory and regenerative molecules. The main advantages of MSC therapy include the safety of the treatment, the possibility to use autologous (patient's own) cells, and observations that the therapeutic properties of MSCs can be intentionally regulated by external factors during their preparation. In this review, we provide a survey of the immunoregulatory and regenerative mechanisms in the eye and describe the therapeutic potential of MSC application for corneal damages and retinal diseases.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010379
003      
CZ-PrNML
005      
20250429134535.0
007      
ta
008      
250415s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1177/09636897241312798 $2 doi
035    __
$a (PubMed)39856809
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hermankova, Barbora $u Department of Nanotoxicology and Molecular Epidemiology, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic $1 https://orcid.org/0000000282360012 $7 xx0277971
245    10
$a Perspectives and Limitations of Mesenchymal Stem Cell-Based Therapy for Corneal Injuries and Retinal Diseases / $c B. Hermankova, E. Javorkova, K. Palacka, V. Holan
520    9_
$a The eye represents a highly specialized organ, with its main function being to convert light signals into electrical impulses. Any damage or disease of the eye induces a local inflammatory reaction that could be harmful for the specialized ocular cells. Therefore, the eye developed several immunoregulatory mechanisms which protect the ocular structures against deleterious immune reactions. This protection is ensured by the production of a variety of immunosuppressive molecules, which create the immune privilege of the eye. In addition, ocular cells are potent producers of numerous growth and trophic factors which support the survival and regeneration of diseased and damaged cells. If the immune privilege of the eye is interrupted and the regulatory mechanisms are not sufficiently effective, the eye disease can progress and result in worsening of vision or even blindness. In such cases, external immunotherapeutic interventions are needed. One perspective possibility of treatment is represented by mesenchymal stromal/stem cell (MSC) therapy. MSCs, which can be administered intraocularly or locally into diseased site, are potent producers of various immunoregulatory and regenerative molecules. The main advantages of MSC therapy include the safety of the treatment, the possibility to use autologous (patient's own) cells, and observations that the therapeutic properties of MSCs can be intentionally regulated by external factors during their preparation. In this review, we provide a survey of the immunoregulatory and regenerative mechanisms in the eye and describe the therapeutic potential of MSC application for corneal damages and retinal diseases.
650    _2
$a lidé $7 D006801
650    12
$a transplantace mezenchymálních kmenových buněk $x metody $7 D045164
650    12
$a nemoci retiny $x terapie $7 D012164
650    12
$a mezenchymální kmenové buňky $x cytologie $7 D059630
650    12
$a poranění rohovky $x terapie $7 D065306
650    _2
$a zvířata $7 D000818
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Javorkova, Eliska $u Department of Nanotoxicology and Molecular Epidemiology, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic $u Department of Cell Biology, Faculty of Science, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000198136026 $7 xx0300609
700    1_
$a Palacka, Katerina $u Department of Nanotoxicology and Molecular Epidemiology, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic $u Department of Cell Biology, Faculty of Science, Charles University, Prague, Czech Republic
700    1_
$a Holan, Vladimir $u Department of Nanotoxicology and Molecular Epidemiology, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic $u Department of Cell Biology, Faculty of Science, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000220113390 $7 nlk20050169384
773    0_
$w MED00001075 $t Cell transplantation $x 1555-3892 $g Roč. 34 (2025), s. 9636897241312798
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39856809 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134531 $b ABA008
999    __
$a ok $b bmc $g 2311624 $s 1247460
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 34 $c - $d 9636897241312798 $e - $i 1555-3892 $m Cell transplantation $n Cell Transplant $x MED00001075
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...